Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller [Yahoo! Finance]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Yahoo! Finance
Natera, Inc. (NASDAQ:NTRA) is the largest holding in the 13F portfolio of Duquesne Capital. The stock has consistently appeared in the portfolio of the fund since the third quarter of 2022. Back then, this position comprised just over 400,000 shares. The fund steadily increased this to over 3.5 million shares by the end of the fourth quarter of 2024. Since then, the stake has been trimmed. Filings for the fourth quarter of 2025 show that the fund owned 2.5 million shares in the firm, down over 21% compared to filings for the previous quarter. 5 Best Tech Stocks Under $50 to Buy Now A person with a cell phone who is looking for new stocks A major catalyst for Wall Street interest in Natera, Inc. (NASDAQ:NTRA) is the explosive growth of Signatera, Natera's molecular residual disease (MRD) test. In early 2026, data showed that over 50% of all oncologists in the US had ordered a Signatera test in the previous quarter. Oncology test volumes grew by 55% year-over-year in Q4 2025. Ins
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera (NTRA) is now covered by William Blair. They set an "outperform" rating on the stock.MarketBeat
- Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell LymphomaBusiness Wire
- Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related PatentsBusiness Wire
- 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology PlatformBusiness Wire
- Natera (NTRA) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NTRA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "buy" to "hold".MarketBeat
NTRA
Earnings
- 2/26/26 - Miss
NTRA
Sec Filings
- 4/9/26 - Form 3
- 4/8/26 - Form 4
- 4/3/26 - Form 4
- NTRA's page on the SEC website